1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

US FDA's Device-Focused Patient Engagement AdComm Tackles Trial Challenges

FDA's new Patient Engagement Advisory Committee will discuss patient perspectives on device clinical trials at its first scheduled meeting.

Two years after its launch, US FDA's device center will convene the first meeting of its Patient Engagement Advisory Committee in October to discuss patient perspectives in clinical trials.

On July 25, CDRH Director Jeff Shuren and Kathryn O’Callaghan, assistant director for strategic programs at the center announced the first meeting of the Patient Engagement Advisory Committee,...

PEAC Roster
  • Paul T. Conway (Chair), president of the American Association of Kidney Patients
  • Katherine Seelman (Consumer Representative), Retired professor of rehabilitation science and technology, University of Pittsburgh
  • Cynthia...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.